Skip to main content
SpringerLink
Log in

Management of antipsychotic-induced constipation requires more attention

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Constipation is a common adverse effect of antipsychotic therapy that remains understudied and underreported. Weekly constipation screening, continuous long-term monitoring, reducing the antipsychotic dose and switching to a different antipsychotic with less risk of constipation are useful preventive measures. Recommended options for the treatment of antipsychotic-induced constipation include lifestyle changes, behavioural therapy, laxatives and novel drugs (e.g. lubiprostone, prucalopride). Patients who are refractory to pharmacological treatment may be candidates for surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Xu Y, Amdanee N, Zhang X. Antipsychotic-induced constipation: a review of the pathogenesis, clinical diagnosis, and treatment. CNS Drugs. 2021;35(12):1265–74.

    Article  Google Scholar 

  2. Demler TL, Krieger K. Challenges associated with treating and preventing antipsychotic-induced constipation: considerations and cautions when prescribing novel interventions. Int Clin Psychopharmacol. 2021;36(1):12–7.

    Article  Google Scholar 

  3. Sarangi A, Armin S, Vargas A, et al. Management of constipation in patients with schizophrenia—a case study and review of literature. Middle East Curr Psychiatry. 2021;28(1):1–7.

    Article  Google Scholar 

  4. Lu Y-S, Chen Y-C, Kuo S-H, et al. Prevalence of antipsychotic drugs related to constipation in patients with schizophrenia. Taiwanese J Psychiatry. 2016;30(4):294–9.

    Google Scholar 

  5. Shirazi A, Stubbs B, Gomez L, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17:863.

    Article  Google Scholar 

  6. Chougule A, Praharaj SK, Bhat SM, et al. Prevalence and factors associated with clozapine-related constipation: an observational study. J Clin Psychopharmacol. 2018;38(1):42–6.

    Article  CAS  Google Scholar 

  7. Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal “slow gut” reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31:699–709.

    Article  CAS  Google Scholar 

  8. American Gastroenterological A, Bharucha AE, Dorn SD, et al. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211–7.

    Article  Google Scholar 

  9. Bailey L, Varma S, Ahmad N, et al. Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther Adv Psychopharmacol. 2015;5(5):256–62.

    Article  CAS  Google Scholar 

  10. Every-Palmer S, Lentle RG, Reynolds G, et al. Spatiotemporal mapping techniques show clozapine impairs neurogenic and myogenic patterns of activity in the colon of the rabbit in a dose-dependent manner. Front Pharmacol. 2017. https://doi.org/10.3389/fphar.2017.00209.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Jani B, Marsicano E. Constipation: evaluation and management. Mo Med. 2018;115(3):236–40.

    PubMed  PubMed Central  Google Scholar 

  12. Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat Rev Dis Primers. 2017. https://doi.org/10.1038/nrdp.2017.95.

    Article  PubMed  Google Scholar 

  13. Hayat U, Dugum M, Garg S. Chronic constipation: update on management. Cleve Clin J Med. 2017;84(5):397–408.

    Article  Google Scholar 

  14. Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69:759–86.

    Article  CAS  Google Scholar 

  15. Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013;33(5):713–4.

    Article  Google Scholar 

  16. Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for antipsychotic-related constipation. Schizophr Bull. 2017;43(3):490–2.

    Article  Google Scholar 

  17. Meyer JM, Cummings MA. Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014;130:71–2.

    Article  CAS  Google Scholar 

  18. Torrico TJ, Kaur S, Dayal M, et al. Lubiprostone for the treatment of clozapine-induced constipation: a case series. Cureus. 2022;14(6):e25576.

    PubMed  PubMed Central  Google Scholar 

  19. Nakamura M, Nagamine T. Prevalence and predictors of laxatives use in clozapine-related constipation: an observational study. Int Clin Psychopharmacol. 2021;36:162–7.

    Article  Google Scholar 

  20. Thomas N, Jain N, Connally F, et al. Prucalopride in clozapine-induced constipation. Aust NZ J Psychiatry. 2018;52(8):804–9.

    Article  Google Scholar 

  21. Damodaran I, Hui KO, Nordin ASA, et al. An open-label, head to head comparison study between prucalopride and lactulose for clozapine induced constipation in patients with treatment resistant schizophrenia. Healthcare. 2020;8:533.

    Article  Google Scholar 

  22. George J, Hotham R, Melton W, et al. Clozapine-induced stercoral colitis: a surgical perspective. BMJ Case Rep. 2019;12: e227718.

    Article  Google Scholar 

  23. Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Aust Psychiatry Bull R Aust NZ Coll Psychiatr. 2008;16(3):216–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Hannah A. Blair

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

H. A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. Management of antipsychotic-induced constipation requires more attention. Drugs Ther Perspect 38, 356–361 (2022). https://doi.org/10.1007/s40267-022-00935-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-022-00935-5

Search

Navigation